Bioresponsive Nanocarriers For Controlled And Targeted Delivery To Efficiently Treat Inflammatory Bowel Disease (IBD)
Funder
National Health and Medical Research Council
Funding Amount
$316,449.00
Summary
Despite considerable progress in treatment of Inflammatory Bowel Diseases, current treatments suffer from many disadvantages such as side effects, lack of efficacy in many patients, and development of drug dependence. Using state of art nanotechnology, novel nanoparticles will be developed to enhance the delivery to the intestine and efficacy of Budesonide (an anti-inflammatory steroid). This research promises to find safer and more effective ways to treat these diseases.
Venoms To Drugs: Characterizing The Molecular Interactions Between Venom Peptides And Ion Channels With A View To Rational Drug Design
Funder
National Health and Medical Research Council
Funding Amount
$316,449.00
Summary
The conventional approach to drug development is reaching a state of crisis as it is producing fewer new drugs at increasing cost. A promising alternative is to harness the rich and diverse chemistry of venom peptides. This project aims to understand the mechanism by which venom peptides achieve their pharmacological activity. This knowledge is essential for venom-based drug design for treating diseases ranging from nervous systems disorders, stroke, chronic pain and psychiatric illnesses.
Almost every member of clinical staff in hospitals now carries a smartphone or tablet. These devices can improve staff performance when life-saving information such as reminders of complex procedures during medical emergencies are delivered in a clear way. This fellowship applies design processes used in other high-risk industries such as in military and nuclear power settings to devise ‘e-aids’ for clinicians to improve outcomes in health emergencies.
Structural Studies Of The Jak And Abl Kinases: A Prerequisite For Drug Design
Funder
National Health and Medical Research Council
Funding Amount
$360,965.00
Summary
Protein tyrosine kinases (PTK) are a large, pivotal family of signalling molecules implicated in diseases such as cancer and immune related disorders. This fellowship aims to develop more potent kinase inhibitors of a number of PTKs using Cytopia’s drug discovery capability coupled with the X-ray crystallography expertise within Monash University. This innovative approach will permit a rational structure-based drug discovery platform to be established and will lead to the creation of a portfolio ....Protein tyrosine kinases (PTK) are a large, pivotal family of signalling molecules implicated in diseases such as cancer and immune related disorders. This fellowship aims to develop more potent kinase inhibitors of a number of PTKs using Cytopia’s drug discovery capability coupled with the X-ray crystallography expertise within Monash University. This innovative approach will permit a rational structure-based drug discovery platform to be established and will lead to the creation of a portfolio of phase I therapeutics, which will be of substantial benefit in the medical health area.Read moreRead less
Structure Determination Of Fms And Kit Kinases And Their Inhibtors For Directed Drug Design
Funder
National Health and Medical Research Council
Funding Amount
$373,250.00
Summary
Tyrosine kinases are a large and important family of enzymes that play a fundamental role in the control and communication between cells. When damaged or uncontrolled, these enzymes can contribute to the development of diseases such as cancer and immune related disorders. This proposal aims to develop therapeutics targeted at the tyrosine kinases using a combination of the Structure Biology expertise at Monash University and the drug discovery platform technologies of Cytopia Pty Ltd. Promising ....Tyrosine kinases are a large and important family of enzymes that play a fundamental role in the control and communication between cells. When damaged or uncontrolled, these enzymes can contribute to the development of diseases such as cancer and immune related disorders. This proposal aims to develop therapeutics targeted at the tyrosine kinases using a combination of the Structure Biology expertise at Monash University and the drug discovery platform technologies of Cytopia Pty Ltd. Promising drug candidates already identified by Cytopia will be analysed at their site of action using X-ray crystallography. This information will enable a rational process of modification and improvement of the candidate drugs. The development of a range of therapeutics for Phase I clinical trials will be of enormous benefit to Australia�s medical industry and pubic health.Read moreRead less
Broad Spectrum Inhibition Of An Enzyme Antibiotic Target
Funder
National Health and Medical Research Council
Funding Amount
$321,534.00
Summary
There is a well-documented need to replenish the antibiotic pipeline with new products to combat the rise of drug resistant bacteria. In this project, the enzyme dihydrodipicolinate synthase (DHDPS) is targetted which is essential to bacterial viability. A number of independent but synergistic drug discovery approaches are investigated to develop and test DHDPS inhibitors in the pursuit of a novel class of antibiotics.
Design And Evaluation Of Inhibitors Targeting Serine Proteases In Blood To Alleviate Systemic Inflammatory Response To Coronary Artery Bypass Graft Surgery
Funder
National Health and Medical Research Council
Funding Amount
$317,559.00
Summary
Over 20,000 Australians undergo bypass surgery each year with a 3% mortality rate linked to complications from the procedure. One such common complication is caused by the body’s immune system being activated when the blood comes in contact with the blood bypass pump machine. This project aims to develop new medicines to block this activation of the immune system during bypass surgery to reduce complications and mortality associated with this procedure.
Rationally Designed Targeted Core Shell Nano-Construct For Improved Anticancer Effects And Enhanced Bone Fracture Healing In Breast Cancers Metastasised To Bone
Funder
National Health and Medical Research Council
Funding Amount
$318,768.00
Summary
The main objective of the project is to develop and evaluate a single therapeutic system comprising chemotherapeutic as well as bone fracture healing agent, which will overcome the drawbacks of the conventional treatment for skeletal bone metastasised breast cancers. This therapeutic system will specifically accumulates in the tumour sites and release the chemotherapeutic enabling anticancer effects, followed by the slow release of bone fracture healing agent results in healing of fractures.
Development Of Small Molecule Antagonists Of HGF/SF And MET Signalling To Treat Metastatic Cancer
Funder
National Health and Medical Research Council
Funding Amount
$353,866.00
Summary
The spread of cancer throughout the body, metastasis, is the major cause of death from cancer. The MET receptor plays a crucial role in over 60% of all metastases and several approaches to block its activity are currently in clinical trials. This project will use a new approach to develop small molecule inhibitors that block the MET receptor from interacting with another protein, HGF/SF. Small molecules that block this interaction will be highly effective treatments against metastatic cancers.